Eterna Therapeutics Inc. announced it has entered into an option agreement with Exacis Biotherapeutics Inc. granting Eterna the right to negotiate an exclusive, worldwide license to develop and commercialize up to four iPS cell-derived natural killer cell ("iNK") and/or T cell ("iT") programs for hematologic malignancies and solid tumors. Exacis makes its cells using non-viral, mRNA-based cell engineering, including a proprietary 'stealthing' approach designed to increase the persistence of therapeutic cells in vivo and minimize or eliminate the need for patient pre- conditioning. Exacis' technology includes high-yield manufacturing processes and the ability to add advanced targeting molecules, including CARs and TCRs.

Under the agreement, Eterna and Exacis have until December 31, 2022 to negotiate and execute a license agreement.